scispace - formally typeset
Y

Yilong Zhang

Researcher at Merck & Co.

Publications -  15
Citations -  10915

Yilong Zhang is an academic researcher from Merck & Co.. The author has contributed to research in topics: Medicine & Gene. The author has an hindex of 9, co-authored 9 publications receiving 4759 citations. Previous affiliations of Yilong Zhang include New York University.

Papers
More filters
Journal ArticleDOI

Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2

Evan Bolyen, +123 more
- 01 Aug 2019 - 
TL;DR: QIIME 2 development was primarily funded by NSF Awards 1565100 to J.G.C. and R.K.P. and partial support was also provided by the following: grants NIH U54CA143925 and U54MD012388.
Posted ContentDOI

QIIME 2: Reproducible, interactive, scalable, and extensible microbiome data science

Evan Bolyen, +119 more
- 24 Oct 2018 - 
TL;DR: QIIME 2 provides new features that will drive the next generation of microbiome research, including interactive spatial and temporal analysis and visualization tools, support for metabolomics and shotgun metagenomics analysis, and automated data provenance tracking to ensure reproducible, transparent microbiome data science.
Journal ArticleDOI

Cigarette smoking and the oral microbiome in a large study of American adults.

TL;DR: In a study of 1204 US adults, this article assessed the relationship of cigarette smoking with the oral microbiome and found that current smokers had lower relative abundance of the phylum Proteobacteria (4.6%) compared with never smokers (11.7%) with no difference between former and never smokers.
Journal ArticleDOI

Author Correction: Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2.

Evan Bolyen, +125 more
- 01 Sep 2019 - 
TL;DR: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Journal ArticleDOI

PM2.5 air pollution and cause-specific cardiovascular disease mortality

TL;DR: Long-term exposure to fine particulate air pollution is associated with ischaemic heart disease and stroke mortality, with excess risks occurring in the range of and below the present US long-term standard for ambient exposure to PM2.5, indicating the need for continued improvements in air pollution abatement for CVD prevention.